Jukka Hartikka
Associate Director of Vaccinology, Vical Inc.
Associate Director of Vaccinology searching for new challenges in Business Development and Technology Licensing for adjuvants for infectious diseases or cancer applications. Experience in R&D, product discovery, technology development and team management within biotechnology and pharmaceutical companies. Played a key role in several pre-clinical IND-enabling studies. Leader of teams evaluating needle-free injectors and electroporation devices to enhance vaccine potency.
62 contactsSpear headed development of a proprietary adjuvant for protein- and peptide-based vaccines. Responsible for in vivo testing of formulations & vectors for vaccines. Identified a strong vector and a novel adjuvant currently being evaluated in Phase I clinical trial with DNA-based pandemic flu vaccine.
1988 - 1991Studied growth requirements of central cholinergic, dopaminergic and serotonergic neurons at the Department of Preclinical Research. Identified factors which increase their survival, revealing novel possibilities for the treatment of Parkinson's and Alzheimer's diseases.